EcoGrid SunGrid Expansion & VitaPharm ROE Analysis – Capital Budgeting & DuPont Review
QUESTION 1 (73 marks)
EcoGrid Solutions Ltd (Eco) is a leading provider of eco-friendly gas-powered shower systems. Their innovative technology, which utilises state-of-the-art gas geysers, ensures a consistent supply of hot water while minimising environmental impact. A gas geyser is a type of water heater that uses natural gas or liquid petroleum gas (LPG) to heat water. Eco specialises in providing these shower systems to residential and commercial customers. The entity has a 31 July financial year end.
Eco has recently started exploring an opportunity to expand their product and services line to include Solar Power solutions. This will entail supplying and installing solar panels, inverters, and batteries for residential and commercial customers. Eco recognises the growing demand for renewable energy sources in South Africa and sees such a project as a strategic move to diversify its energy portfolio. The Solar Power project will be called SunGrid and will kick off on 1 August 2025.
Market research has provided insights into the optimal pricing structure of the product, as well as the expected sales figures. Eco’s Financial Accountant determined that the project should remain active for 5 years.
The initial capital cost of new equipment for the SunGrid project would be R25 000 000, payable before the project commences on 1 August 2025. After 5 years, the residual value of the equipment would total R9 000 000. The equipment is to be depreciated over a five (5) year period on a straight-line basis. According to section 12C of the South African Income Tax Act, the equipment will qualify for a wear-and- tear allowance of 40% of the cost in the first year and 20% of the cost in the subsequent years.
In expectation of the new venture, Eco has already purchased a bigger truck for the transport of large solar panels at a cost of R1 800 000. Assume depreciation is in line with the tax wear and tear allowance. The newly purchased truck will also reduce the after-tax transport costs for the existing gas-powered shower system product line by R45 000 per year.
Additional information regarding SunGrid expansion:
Eco has spent R380 000 on market research to determine whether this project is viable. The report also detailed the following information:
- SunGrid’s predicted Earnings Before Interest and Tax (EBIT) in the first operational year can be projected using the following probabilities: 35%: R12 500 000, 40%: R14 000 000, and 25%: R16 500 000. The entity’s
operational profit (EBIT) is expected to grow by 2% annually throughout the project.
- Working Capital investments at the end of each year are expected to be as follows and will be recovered at the end of the project’s life:
31 July | 31 July | 31 July | 31 July | 31 July | |
2026 | 2027 | 2028 | 2029 | 2030 | |
(R) | (R) | (R) | (R) | (R) | |
Inventory | 4 550 000 | 4 900 000 | 5 700 000 | 6 200 000 | 6 500 000 |
Debtors | 1 250 000 | 2 400 000 | 2 700 000 | 2 850 000 | 3 150 000 |
Creditors | (2 800 000) | (3 200 000) | (3 550 000) | (3 800 000) | (3 950 000) |
Eco has a debt-to-equity ratio of 25%. They only have one debt instrument with a cost of debt rate of 12%.
Eco is not listed on the Johannesburg Stock Exchange (JSE), and therefore, the equity beta of the entity is not readily available. GasSol Technologies Ltd. is a similar entity listed on the JSE. This entity has a debt-to-equity ratio of 34% and a beta of 1.2. The average return offered in the renewable energy sector is 12.5%, whereas the long- term risk of the RSA government bonds’ rate of return is 9.2%.
Below is an extract from Eco’s latest Statement of Financial Position:
31 July 2025 | |
Cash | R3 850 000 |
Property, Plant and Equipment | R12 250 000 |
Intangible Assets | R985 000 |
Other non-current assets | R1 125 000 |
Eco faced many operating challenges in the past financial year (ending 31 July 2025). This resulted in an assessed loss of R4 500 000. The assessed loss is not ring-fenced.
Eco’s current predicted earnings before tax (excluding SunGrid) are expected to be as follows:
31 July 2026 | 31 July 2027 | 31 July 2028 | |
Earnings before tax | R2 100 000 | R2 400 000 | R2 900 000 |
The South Africa Income Tax rate applicable to companies is 27% and is expected to remain the same throughout the 5-year period.
Ignore Value Added Tax (VAT).
REQUIRED QUESTION 1 | TOTAL |
1.1 Advise EcoGrid Solutions on whether they should expand their | |
business by accepting the SunGrid project. Make use of the Net Present | |
Value AND Internal Rate of Return Capital Budgeting techniques. | 65 |
Should you purposefully exclude an item from the valuation, indicate | |
this in your answer as well as the motivation for opting to do so. | |
Communication skill: Logical argument | 1 |
1.2 Describe the process Eco’s Financial Accountant used to determine that the SunGrid project should have a five-year lifespan. Additionally, clarify whether this five-year lifespan is guaranteed to remain unchanged and how the Financial Manager will assess this. | 7 |
TOTAL QUESTION 1 | 73 |
QUESTION 2 (27 marks)
VitaPharm is a leading South African pharmaceutical company committed to advancing global health through innovative research, cutting-edge technology, and comprehensive healthcare solutions. Founded in 1990, VitaPharm has grown to become a trusted name in the pharmaceutical industry. VitaPharm is listed on the JSE and has a 28 February financial year end.
VitaPharm faced many challenges during the past financial year, including increased electricity and fuel costs. Furthermore, much of the equipment at the pharmacies had to be replaced due to age. There is also a new competitor on the South African market that provides the same products and services as VitaPharm. The stakeholders are concerned about the Return on Equity of the entity and have instructed the Chief Financial Officer to perform a detailed financial analysis to determine the cause of the reduction in the Return on Equity (ROE) over the past year. Below is the latest audited financial information for VitaPharm:
Statement of comprehensive income for the year ended 28 February 2025:
2025 (R) | 2024 (R) | |
Revenue from contracts with customers Cost of sales | 31 283 476 (23 066 929) | 32 663 513 (25 076 217) |
Gross profit Other income | 8 216 547 2 907 844 | 7 587 296 2 586 591 |
Total income Other expenses | 11 124 391 (9 345 144) | 10 173 887 (8 429 702) |
Operating profit before interest and equity accounted earnings | 1 779 247 | 1 744 185 |
Net financing costs | (439 936) | (350 236) |
– Finance income | 26 297 | 20 210 |
– Finance costs | (466 233) | (370 446) |
Profit from associates and joint ventures | 45 270 | 22 779 |
Profit before taxation Taxation | 1 384 581 (364 093) | 1 416 728 (389 181) |
Total profit for the year, net of taxation | 1 020 488 | 1 027 547 |
Statements of financial position at 28 February 2025:
2025 (R) | 2024 (R) | |
ASSETS | ||
Non-current assets | 9 578 031 | 6 067 828 |
Property, plant and equipment | 7 799 705 | 4 429 226 |
Intangible assets | 1 335 134 | 1 270 255 |
Investments | 208 221 | 194 403 |
Loans receivable | 68 603 | – |
Deferred taxation | 166 368 | 173 944 |
Current assets | 10 922 955 | 9 447 980 |
Inventories | 8 662 558 | 6 356 781 |
Trade and other receivables | 2 231 553 | 2 583 384 |
Loans receivable | 126 111 | 214 062 |
Taxation receivable | 18 362 | 6 368 |
Cash and cash equivalents | 884 371 | 287 385 |
Total Assets | 21 500 986 | 15 515 808 |
EQUITY AND LIABILITIES | ||
Equity and reserves | 2 472 124 | 1 900 395 |
Share capital | 1 155 554 | 1 155 554 |
Retained earnings | 1 865 235 | 1 554 837 |
Other reserves | (176 541) | (709 601) |
Non-controlling interest | 58 569 | 31 295 |
Total Equity | 5 374 941 | 3 932 480 |
Non-current liabilities | 3 842 967 | 3 232 905 |
Lease liability | 2 486 298 | 2 660 592 |
Loans payable | 1 282 337 | 501 479 |
Deferred taxation | 74 332 | 70 834 |
Current liabilities | 12 283 078 | 8 350 423 |
Trade and other payables | 6 863 682 | 6 103 666 |
Lease liability | 581 827 | 567 043 |
Loans payable | 3 388 341 | 797 475 |
Employee-related obligations | 265 241 | 292 871 |
Deferred revenue (contract liability) | 83 897 | 77 170 |
Contingent consideration | – | – |
Taxation payable | 48 947 | 64 644 |
Bank overdraft | 1 051 143 | 447 554 |
Total equity and liabilities | 21 500 986 | 15 515 808 |
The Junior Accountant was tasked by the CFO to provide the following additional information based on the financial statements provided:
2025 R | 2025 Industry sector | 2024 R | |
Net profit | 1 020 488 | 1 027 547 | |
Sales | 31 283 476 | 32 663 513 | |
Total Assets | 21 500 986 | 15 515 808 | |
Total Equity | 5 374 941 | 3 932 480 | |
NP % | 3.26% | 6.5% | 3.14% |
ROA | 4.75% | 7.54% | 6.63% |
ROE | 18.99% | 21.1% | 26.13% |
Total Asset Turnover | 1.45 | 2 | 2.11 |
Financial Leverage multiplier | 4 | 3.12 | 3.96 |
REQUIRED QUESTION 2 | TOTAL |
2.1 Explain why using the Du Pont Analysis would assist in determining | |
the cause of a decrease in the Return on Equity. | 4 |
Communication skill: Clarity of expression | 1 |
2.2 Discuss any CONCERNS regarding VitaPharm’s 2025 financial | |
performance, AND state possible causes for each concern | 21 |
discussed. | |
1 | |
Communication skill: Clarity of expression | |
TOTAL QUESTION 2 | 27 |
Accounting Assignment Answers: Expert Answers on Above Taxation Questions
The decision with respect to acceptance or rejection of a project can be made by calculating npv and IRR. In the given project of EcoGrid, the calculation of npv and IRR indicates that it is good to accept SunGrid because of having a positive npv and IRR is greater than WACC. The project life of 5 year is considered reasonable.
Similarly in respect to VitaPharm, the calculation using DuPont analysis suggests that the profitability margin has been declining, the asset turnover is poor and there is high leverage which leads to declining return on equity.
Disclaimer: This answer is a model for study and reference purposes only. Please do not submit it as your own work. |
Want Detailed Answers with References?
Check Samples on Accounting Subject Written by Experts
Related answer
Online PPE Business Costing and Investment Proposal
Construction Accounting, Disruptions & Life-Cycle Costing
Reef Ltd & Ray Ltd Consolidation | IFRS Group Accounts 2024
Flowers Group Consolidation Case – 30 June 2025
Accounting & Managerial Finance — EOQ, Ratios, CVP
Budgets, Ratio Analysis & Capital Financing in Accounting
Established Manufacturers Case Study & Financial Analysis
Cosmed Limited: 2023 Cash Flows, 2024 Ratios & 2026 Project
Financial Accounting Assignment – VAT, Journals & More
Tax Case Study: HOD Pty Ltd & Special Trust Implications